Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

The following is a summary of “Association between incretin-based drugs and risk of cholangiocarcinoma among patients with ...

A dozen GLP-1 receptor agonists and coagonists demonstrated effectiveness for weight loss in adults with obesity and without ...

For patients with diabetes undergoing a surgical procedure, an active perioperative glucagon-like peptide-1 receptor agonist ...

The following is a summary of “Treatment of Hypothalamic Obesity With GLP-1 Analogs,” published in the November 2024 issue of Endocrinology by Dimitri and Roth. Damage to hypothalamic nuclei or ...

With three meds approved for weight management and several on the way, these may make a dent in the obesity epidemic.

There are over 300 glucagon-like peptide-1 receptor (GLP-1R) drugs in an active stage of development as the astounding success of Novo Nordisk’s GLP-1R obesity drug, Wegovy, has ignited a surge ...

Cancer researchers found that patients on GLP-1s had significant risk reductions for 10 of 13 obesity-associated cancers.

McDonald's shares underperformed in 2024, likely due to the rise of GLP-1 medications. Learn why MCD stock is a Sell.

Data from Hengrui’s Phase II trial for its GLP-1/GIP product demonstrated a statistically significant mean weight loss of ...

Patients with obesity and comorbid cardiovascular disease were more likely to ration prescription drugs than those without obesity.